EltaMD UV Clear Blemish-Prone & Oil Balancing SPF 50
Introducing a breakthrough in suncare from the #1 Dermatologist Recommended Professional Sunscreen Brand. EltaMD UV Clear Blemish-Prone & Oil Balancing SPF 50 is a lightweight, hybrid sunscreen specifically designed for and tested on acne-prone skin. This advanced formula allows you to protect and correct without compromise, offering a long-desired solution for those often forced to choose between sun protection and clear skin.
Formulated with 5% Niacinamide and Zinc-AOX Pro Technology, this non-comedogenic and non-acnegenic SPF delivers broad-spectrum protection while clinically improving the appearance of skin imperfections. It is clinically proven to reduce visible blemishes, excess oil, and pore size, promoting a visibly clearer, healthier-looking complexion over time*.
The lightweight, non-greasy texture absorbs quickly with a transparent natural finish, making it ideal for daily wear under makeup or on its own. (net wt 1.7 oz/48 g)
*12-week clinical study, 43 subjects
Original: $49.00
-70%$49.00
$14.70
Description
Introducing a breakthrough in suncare from the #1 Dermatologist Recommended Professional Sunscreen Brand. EltaMD UV Clear Blemish-Prone & Oil Balancing SPF 50 is a lightweight, hybrid sunscreen specifically designed for and tested on acne-prone skin. This advanced formula allows you to protect and correct without compromise, offering a long-desired solution for those often forced to choose between sun protection and clear skin.
Formulated with 5% Niacinamide and Zinc-AOX Pro Technology, this non-comedogenic and non-acnegenic SPF delivers broad-spectrum protection while clinically improving the appearance of skin imperfections. It is clinically proven to reduce visible blemishes, excess oil, and pore size, promoting a visibly clearer, healthier-looking complexion over time*.
The lightweight, non-greasy texture absorbs quickly with a transparent natural finish, making it ideal for daily wear under makeup or on its own. (net wt 1.7 oz/48 g)
*12-week clinical study, 43 subjects
